Carlos Ramirez

San Francisco – February 9, 2023 – Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.

The offering marks the first sizable US life sciences IPO this year. Structure Therapeutics will use the proceeds to develop new oral therapies for the treatment of various diseases, including those impacting the metabolic, cardiovascular and pulmonary systems. Its lead product candidate targets Type 2 diabetes and obesity.

Structure Therapeutics aims to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling it to build a pipeline of product candidates. The company currently focuses on G-protein-coupled receptors as a therapeutic target class.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

Cooley advised ViaCyte, a biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for Type 1 diabetes (T1D), on its definitive agreement to be acquired by global biotechnology company Vertex Pharmaceuticals for $320 million in cash. Partners Rowook Park and Carlos Ramirez, along with associate Lindsey O’Crump, led the Cooley team advising ViaCyte.

Cooley advised Drata, a next-generation security and compliance automation company, on its $100 million Series B financing round, which brings the company’s valuation to $1 billion. Lawyers Ken Rollins, Carlos Ramirez and Dylan Kornbluth led the Cooley team advising Drata.

Cooley advised The Honest Company, a consumer goods company founded by actress Jessica Alba, on its $475 million initial public offering of 29,678,050 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Partners Tom Hopkins, Nicole Brookshire, Siana Lowrey and Sara Semnani led the Cooley team advising Honest.

Cooley advised MannKind on its offering of $200 million principal amount of 2.50% convertible senior notes due 2026. MannKind, whose securities trade on the Nasdaq Global Market under the symbol MNKD, focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Partners Sean Clayton, Mischi a Marca and Jason Savich led the Cooley team.